As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Mon, March 23, 2026 astatine 11:07 AM CDT 4 min read

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals (NASDAQ:TERN), an estimated $5.20 cardinal commercialized based connected quarterly mean pricing.

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Acorn Capital Advisors reduced its presumption successful Terns Pharmaceuticals (NASDAQ:TERN) by 225,000 shares during the 4th fourth of 2025. The estimated worth of the commercialized was astir $5.20 million, calculated utilizing the mean closing terms for the quarter. The quarter-end worth of the remaining involvement reflected marketplace valuation changes.

Acorn Capital Advisors’ Terns Pharmaceuticals holding present represents astir 24% of its 13F AUM aft the caller sale.
Top holdings aft the filing:
- NASDAQ:TERM: $70.55 cardinal (23.9% of AUM)
- NASDAQ:CGON: $46.98 cardinal (15.9% of AUM)
- NASDAQ:URGN: $33.92 cardinal (11.5% of AUM)
- NASDAQ:TRVI: $26.85 cardinal (9.1% of AUM)
- NASDAQ:PBYI: $24.58 cardinal (8.3% of AUM)
As of Monday, shares of Terns Pharmaceuticals were priced astatine $50.08, up a staggering 1,400% implicit the past twelvemonth and importantly outperforming the S&P 500’s astir 15% summation successful the aforesaid period.

Metric

Value

Price (as of Monday)	$50.08
Market Capitalization	$5.5 billion
Net Income (TTM)	($94.44 million)

Terns Pharmaceuticals develops clinical-stage small-molecule therapies targeting non-alcoholic steatohepatitis (NASH) and obesity, with pb candidates including TERN-101, TERN-201, TERN-501, and TERN-601.
The steadfast operates a research-driven concern exemplary focused connected advancing proprietary cause candidates done objective trials, with aboriginal gross anticipated from palmy commercialization and imaginable partnerships.
It targets healthcare providers, biopharmaceutical partners, and patients affected by NASH and metabolic diseases, chiefly wrong the United States and planetary markets.

Terns Pharmaceuticals is simply a clinical-stage biopharmaceutical institution specializing successful the improvement of innovative therapies for NASH and metabolic disorders. With a focused pipeline of differentiated small-molecule cause candidates, the institution leverages precocious probe and objective improvement capabilities to code important unmet aesculapian needs. Its strategy centers connected advancing proprietary compounds done objective milestones to found a competitory presumption successful the biotechnology sector.

Terns has been a standout successful biotech, with shares skyrocketing astir 1,400% successful conscionable a year. That’s the benignant of melodramatic summation that tin usually trigger immoderate repositioning among investors, adjacent those who inactive judge successful the company’s future. And successful this case, adjacent aft scaling back, Terns is inactive the fund’s largest holding, making up astir a 4th of its assets, which is surely an denotation of beardown condemnation alternatively than a retreat.

Operationally, Terns has pivoted to absorption connected oncology, with promising aboriginal efficacy and information results successful treating chronic myeloid leukemia. Plus, the institution wrapped up the twelvemonth with astir $1 cardinal successful cash, providing a runway that extends to 2031 and the flexibility to beforehand toward pivotal trials. That setup has helped shares proceed their ascent since the extremity of past quarter, climbing immoderate 25%.

Ultimately, successful this portfolio, Terns stands gangly among different high-conviction biotech investments and reinforces a strategy that favors asymmetric outcomes implicit specified diversification.

Read Entire Article